anastrozole (Arimidex)

From Aaushi
Jump to navigation Jump to search

Introduction

Tradename: Arimidex.

Indications

Dosage

1 mg PO QD

* 5 years of therapy for prevention of breast cancer

  • 10 years of therapy improves disease-free survival vs 5 years[13]

Tabs: 1 mg.

Adverse effects

Drug interactions

  • inhibits activity of cytochromes P-450 1A2, 2C8/9, 3A4 at high concentrations
  • it is unlikely to cause clinically significant effects on cyt P-450 mediated drug metabolism

Mechanism of action

More general terms

Additional terms

References

  1. Kaiser Permanente Northern California Regional Drug Formulary, 1998
  2. The Prescriber's Letter, vol 6 #11, Nov 1999
  3. The Prescriber's Letter, vol 7 #10, Oct 2000, pg 57
  4. The Prescriber's Letter, vol 8 #2, Feb 2001, pg 10
  5. 5.0 5.1 The Prescriber's Letter, vol 9 #2, Feb 2002, pg 10
  6. Journal Watch 22(17):136, 2002 The ATAC Trialists' Group, Lancet 359:2131, 2002 http://www.thelancet.com/journal/vol359/iss9324/full/llan.359.9324.original_research.21481.1
  7. Prescriber's Letter 12(1): 2005 Arimidex (Anastrozole) for Early Breast Cancer; an Update Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=210113&pb=PRL (subscription needed) http://www.prescribersletter.com
  8. 8.0 8.1 Boccardo F, Rubagotti A, Puntoni M, Guglielmini P, Amoroso D, Fini A, Paladini G, Mesiti M, Romeo D, Rinaldini M, Scali S, Porpiglia M, Benedetto C, Restuccia N, Buzzi F, Franchi R, Massidda B, Distante V, Amadori D, Sismondi P. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol. 2005 Aug 1;23(22):5138-47. Epub 2005 Jul 11. PMID: https://www.ncbi.nlm.nih.gov/pubmed/16009955
  9. 9.0 9.1 Eastell R et al, Effect of anastrozole on bone mineral density: 5-year results from the Anastrozole, Tamoxifen, Alone or in Combination trial 18233230. J Clin Oncol 2008, 26:1051 PMID: https://www.ncbi.nlm.nih.gov/pubmed/18309940
  10. 10.0 10.1 Medical Knowledge Self Assessment Program (MKSAP) 18, American College of Physicians, Philadelphia 2018
  11. 11.0 11.1 Geriatric Review Syllabus, 10th edition (GRS10) Harper GM, Lyons WL, Potter JF (eds) American Geriatrics Society, 2019
    Geriatric Review Syllabus, 11th edition (GRS11) Harper GM, Lyons WL, Potter JF (eds) American Geriatrics Society, 2022
  12. 12.0 12.1 Cuzick J, Sestak I, Forbes JF et al Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial. Lancet. Dec 12, 2019 PMID: https://www.ncbi.nlm.nih.gov/pubmed/31839281 Free Article https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)32955-1/fulltext
  13. 13.0 13.1 Iwase T et al. Postoperative adjuvant anastrozole for 10 or 5 years in patients with hormone receptor-positive breast cancer: AERAS, a randomized multicenter open-label phase III trial. J Clin Oncol 2023 Apr 20; [e-pub]. PMID: https://www.ncbi.nlm.nih.gov/pubmed/37079878 https://ascopubs.org/doi/10.1200/JCO.22.00577

Database